Cellular Biomedicine Group Announces Phase I Results From

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cellular Biomedicine Group Announces Phase I Results From CAR-T Immuno-Oncology Clinical Development Programs

SHANGHAI, China and PALO ALTO, Calif., March 25, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (Nasdaq: CBMG ) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced clinical data from its CAR-T immuno-oncology clinical development programs. The data will be discussed by Dr. Wei (William) Cao, PhD, BM, Chief Executive Officer of Cellular Biomedicine Group, at the 2015 Annual Regen Med Investor Day on March 25 in New York City.

Dr. Cao commented, "We are very pleased with the efficacy and toxicity profile of our CAR-T technology, given the advanced stage of the cancer patients in the trials. With over 3.5 million new cancer patients diagnosed every year in China, developing safer and more effective cancer immunotherapy programs with leading hospitals will serve urgent unmet medical needs. We look forward to additional progress in advancing our CAR-T cell pipeline with further clinical development of our CD19, CD20, CD30 and EGFR-HER1 constructs."

About the Trials

The CAR-T trials were designed and conducted by Chinese PLA General Hospital ("PLAGH", Beijing, also known as "301 Hospital"), led by Principal Investigator Wei Dong Han, MD, PhD, head of PLAGH's cancer immunotherapy department. They studied genetically engineered lymphocyte therapy in treating patients with B-cell leukemia or lymphoma that is relapsed (after stem cell transplantation or intensive chemotherapy) or refractory to available therapeutics. The studies recruited male and female subjects with CD19+ and CD20+ B cell malignancies with no available curative treatment options (such as autologous or allogeneic SCT) that had limited prognosis (several months to < 2 year survival) with currently available therapies.

CAR-T CD19 for Acute Lymphocytic Leukemia (B-cell ALL) Data Analysis

Nine adult patients with relapsed or chemotherapy-refractory B-cell lineage acute lymphocytic leukemia (B-cell ALL) were enrolled in this CAR-CD19 T cell therapy trial. Results showed a complete response (CR) rate of 22.2% (two out of nine patients) and a partial response (PR) rate of 44.4% (four out of nine patients) for an overall response rate (ORR) of 66.7% (six out of nine patients). Further subgroup analysis showed an overall response rate (ORR) of 71.5% (five out of seven patients) in the six CD19 patients with extramedullary involvement and one patient with no extramedullary lesions and treated with autologous CAR-CD19 T cell therapy. In the six CD19 patients with extramedullary leukemia involvement or bulky adenopathy, an overall response rate (ORR) of 66.7% (four out of six patients) was achieved. Two of the nine patients with extramedullary lesions received allogeneic CAR-CD19 T cell therapy (CBM-C19.a1) and had converted mixed to complete donor chimerism at the onset of graft-versus-host disease (GVHD). One of those patients eventually died of GVHD, but the other gradually reached a complete hematologic remission and a partial regression of her extramedullary leukemic lesions. There were two Grade 2-3 toxicities and GVHD Grade 4 toxicities.

This study is registered at www.clinicaltrials.gov as NCT01864889 . 

CAR-T CD20 for Advanced Diffuse Large B Cell Lymphoma (DLBCL ) Data Analysis

The Company also summarized the results of a Phase I clinical trial on CAR-CD20 T cell therapy (CBM-C20.1), which enrolled seven patients with chemotherapy refractory advanced diffuse large B cell lymphomas (DLBCL). One of the two patients with no bulky tumors achieved a 14-month durable and ongoing complete remission by cell infusion only, and another achieved a 6-month tumor regression achieving a complete response (CR) rate of 50% (one out of two patients) and an overall response rate (ORR) of 100% (two out of two patients). Of those patients with bulky tumor burden, four of five patients were evaluable for clinical efficacy. Of those four patients, three achieved three to six month tumor regression for an overall response rate (ORR) of 75% (three out of four patients).

Delayed toxicities related to CAR-CD20 cell infusion are directly correlated to tumor burden, and mainly included, but were not limited to, curable cytokine release symptoms and tumor lysis symptoms, and these results were achieved by combining debulking conditioning regimens in advanced DLBCL patients with bulky tumors. Overall there were three Grade 2-3 toxicities and one Grade 4 toxicity.

This study is registered at www.clinicaltrials.gov as NCT01735604 . Publication source : Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol. 2014 Dec;155(2):160-75. doi: 10.1016/j.clim.2014.10.002. Epub 2014 Oct 16.

Further details of the clinical data may be viewed in the Company's most recent presentation filed on Form 8k with the SEC, which can be found on the Company's website at the following link, http://cellbiomedgroup.com/investor-relations...-overview/ under SEC filings or presentations.

The Company expects to release Phase I clinical data in the third quarter of 2015 from its clinical studies of the CAR-T constructs targeting CD30-positive Hodgkin's lymphoma and EGFR-HER1-positive advanced lung cancer.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers.  Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards.  To learn more about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Sarah Kelly Director of Corporate Communications, CBMG +1 650 566-5064 Vivian Chen Managing Director Investor Relations, Grayling +1 347-481-3711

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 79

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 125

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 115

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Atalanta Takes Formal Verification Into Critical Systems

Updated Category News Views 573

A week of bewildering infrastructure failures is a nasty time to discover nobody can explain the machinery. That was the backdrop for Atalanta CEO and co-founder Anjana Rajan at the National Academies of Sciences, Engineering, and Medicine's Cyber Resilience Forum, which concluded November 20 after two days in Washington. Her central point deserves more attention than the...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 103

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 161

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 100

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading

Top 5 Most Recently Viewed Articles

Secretariat's Legacy Bottled: Bourbon Honors Belmont Win

Updated Category News Views 28

A Toast to Racing History When you think about groundbreaking victories, Secretariat's name is right up there. Now, they’re bottling that history into bourbon. It's not just any day you get a drink inspired by a 31-length victory. Thoroughbred fans and whiskey lovers, listen up because Thirty-One Lengths Bourbon is bringing Secretariat back into the spotlight....

Continue Reading
China Automotive Systems Achieves Record Revenue in 2024

Updated Category News Views 202

Record Revenue Growth at China Automotive Systems China Automotive Systems, Inc. (NASDAQ: CAAS) has reported a remarkable increase in its revenue for the fiscal year 2024, achieving an all-time high of $650.9 million. This represents a significant 12.9% increase from the previous year's revenue of $576.4 million, demonstrating the company's strength in the competitive...

Continue Reading
Future of Energy Storage: A Market Growth Journey Ahead

Updated Category News Views 271

Understanding the Energy Storage Market Potential The global energy storage sector is on the brink of significant growth, projected to escalate from a value of USD 58.9 billion in 2024 to an astonishing USD 204.8 billion by 2033. This remarkable trajectory represents an impressive compound annual growth rate (CAGR) of 14.8%. As the world leans more heavily towards...

Continue Reading
Celebrated Legal Innovators: Reuben Raucher & Blum Shine Bright

Updated Category News Views 116

Reuben Raucher & Blum Earn Legal Visionary Recognition Boutique law firm Reuben Raucher & Blum (RRB), based in Los Angeles, has recently gained significant recognition for its exceptional legal expertise. Partners Tim Reuben and Stephanie Blum have been celebrated as Legal Visionaries in Business of Law magazine. This award acknowledges their remarkable leadership and...

Continue Reading
Baker Hughes Welcomes Ahmed Moghal as New CFO to Drive Growth

Updated Category News Views 294

Baker Hughes Announces New CFO Appointment HOUSTON and LONDON — Baker Hughes Company (NASDAQ: BKR) has officially appointed Ahmed Moghal as the new Chief Financial Officer. Moghal, who has been instrumental in the organization’s financial strategies as the CFO of Industrial & Energy Technology (IET), steps into this pivotal role immediately. His vast experience within...

Continue Reading